A detailed history of Cwm, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Cwm, LLC holds 799 shares of SUPN stock, worth $27,469. This represents 0.0% of its overall portfolio holdings.

Number of Shares
799
Previous 917 12.87%
Holding current value
$27,469
Previous $31,000 32.26%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 09, 2024

SELL
$25.99 - $33.85 $3,066 - $3,994
-118 Reduced 12.87%
799 $21,000
Q1 2024

Apr 05, 2024

BUY
$27.11 - $35.17 $3,226 - $4,185
119 Added 14.91%
917 $31,000
Q4 2023

Feb 01, 2024

BUY
$22.72 - $29.68 $13,881 - $18,134
611 Added 326.74%
798 $23,000
Q3 2023

Oct 11, 2023

BUY
$27.57 - $32.91 $523 - $625
19 Added 11.31%
187 $5,000
Q2 2023

Aug 03, 2023

SELL
$29.91 - $38.73 $5,114 - $6,622
-171 Reduced 50.44%
168 $5,000
Q1 2023

Apr 28, 2023

BUY
$34.93 - $42.03 $2,514 - $3,026
72 Added 26.97%
339 $12,000
Q4 2022

Feb 01, 2023

SELL
$31.09 - $37.88 $466 - $568
-15 Reduced 5.32%
267 $10,000
Q3 2022

Oct 27, 2022

BUY
$28.79 - $35.41 $2,850 - $3,505
99 Added 54.1%
282 $10,000
Q1 2022

Apr 21, 2022

SELL
$28.51 - $32.9 $513 - $592
-18 Reduced 8.96%
183 $6,000
Q4 2021

Jan 31, 2022

BUY
$26.37 - $34.22 $3,744 - $4,859
142 Added 240.68%
201 $6,000
Q4 2019

Sep 14, 2021

BUY
$19.93 - $29.13 $1,175 - $1,718
59 New
59 $2,000
Q4 2019

Jan 27, 2020

SELL
$19.93 - $29.13 $1,175 - $1,718
-59 Closed
0 $0
Q3 2019

Sep 14, 2021

BUY
$25.47 - $33.37 $1,502 - $1,968
59 New
59 $2,000
Q3 2019

Oct 22, 2019

SELL
$25.47 - $33.37 $1,502 - $1,968
-59 Closed
0 $0
Q2 2019

Sep 14, 2021

BUY
$29.96 - $38.87 $1,767 - $2,293
59 New
59 $2,000
Q2 2019

Jul 31, 2019

SELL
$29.96 - $38.87 $1,767 - $2,293
-59 Closed
0 $0
Q1 2019

Sep 02, 2021

BUY
$32.77 - $41.99 $1,572 - $2,015
48 Added 436.36%
59 $0
Q1 2019

Apr 22, 2019

BUY
$32.77 - $41.99 $360 - $461
11 New
11 $0

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.84B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.